Patents by Inventor Raymond A. Chavez

Raymond A. Chavez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11505556
    Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 22, 2022
    Assignee: Xalud Therapeutics, Inc.
    Inventors: Raymond A. Chavez, Stephen Collins
  • Publication number: 20220313785
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 6, 2022
    Applicants: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Raymond A. Chavez, Linda May Rothblum Watkins, Robert Landry
  • Publication number: 20210087202
    Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.
    Type: Application
    Filed: December 12, 2018
    Publication date: March 25, 2021
    Applicant: Xalud Therapeutics, Inc.
    Inventors: Raymond A. Chavez, Stephen Collins
  • Publication number: 20200093892
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Application
    Filed: October 31, 2019
    Publication date: March 26, 2020
    Applicants: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Raymond A. Chavez, Linda May Rothblum Watkins, Robert Landry
  • Patent number: 10512672
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: December 24, 2019
    Assignees: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Raymond A. Chavez, Linda R. Watkins, Robert Landry
  • Publication number: 20190112354
    Abstract: This invention relates to methods and compositions for overcoming the dose-dependent down regulation of interleukin 10 (IL-10) by expressing, in addition to an interleukin 10 (IL-10) peptide, an IL-10 receptor type 1 (IL-10R1) peptide. The methods have use in treating a variety of diseases and symptoms, including but not limited to neuropathic or chronic pain; symptoms and physiological damage associated with multiple sclerosis, spinal cord injury, ALS, neuroinflammation, arthritis and other diseases of the joint; and autoimmune diseases.
    Type: Application
    Filed: April 21, 2017
    Publication date: April 18, 2019
    Inventors: John Forsayeth, Raymond Chavez, Linda Watkins, Peter Grace
  • Publication number: 20160235816
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Application
    Filed: July 17, 2014
    Publication date: August 18, 2016
    Inventors: Raymond A. CHAVEZ, Linda R. WATKINS, Robert LANDRY
  • Publication number: 20130337556
    Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.
    Type: Application
    Filed: July 23, 2013
    Publication date: December 19, 2013
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Linda Watkins, Travis Hughes, Raymond Chavez
  • Patent number: 8524678
    Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: September 3, 2013
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Linda May Rothblum Watkins, Travis Hughes, Raymond A. Chavez
  • Publication number: 20110306559
    Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.
    Type: Application
    Filed: December 23, 2009
    Publication date: December 15, 2011
    Applicant: SANGAMO BIOSCIENCES, INC.
    Inventors: John R.M. Forsayeth, Raymond A. Chavez, Trevor N. Collingwood
  • Patent number: 7749490
    Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: July 6, 2010
    Assignee: The Regents of the University of Colorado
    Inventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20100028296
    Abstract: Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia.
    Type: Application
    Filed: May 1, 2006
    Publication date: February 4, 2010
    Inventors: Raymond A. Chavez, Kirk W. Johnson, Jennifer Shumilla, Laura Sanftner
  • Publication number: 20090208563
    Abstract: Methods of delivering transgenes to target cells using plasmids comprising viral inverted terminal repeat (ITR) sequences are described. Such plasmids are capable of directing sustained transgene expression in target cells in rats provided that at least one adeno-associated virus (AAV) ITR sequence is present in the plasmid, regardless of whether that ITR is located upstream or downstream of the transgene. In a particular embodiment, plasmids comprising one or more AAV ITR sequence and an IL-10 transgene are shown to be effective in sustained reversal of pain in an animal model of neuropathic pain.
    Type: Application
    Filed: May 26, 2006
    Publication date: August 20, 2009
    Inventors: Linda May Rothblum Watkins, Travis Hughes, Raymond A. Chavez
  • Publication number: 20090035256
    Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.
    Type: Application
    Filed: May 26, 2006
    Publication date: February 5, 2009
    Inventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20060040880
    Abstract: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention may comprise a nucleic acid sequence encoding a protein of the invention, which nucleic acid sequence may optionally be provided as a plasmid or within a virus or other vector for delivery to a target cell or tissue. Methods of treating neuropathic pain involving treatment of subject with the compositions of the invention are also provided. Exemplary target genes for the treatment of neuropathic pain include VR1, NaV1.8, and TrkA.
    Type: Application
    Filed: April 8, 2005
    Publication date: February 23, 2006
    Inventors: John Forsayeth, Raymond Chavez, Trevor Collingwood, Andrew McNamara, Yann Jouvenot
  • Patent number: 6610827
    Abstract: The present invention provides novel potassium channel subunits (denoted Kv-SL1 and Kv-SL2, and collectively as Kv-SL) and polynucleotides which identify and encode them. The invention also provides expression vectors and host cells comprising nucleic acid sequence encoding Kv-SL. The invention also provides antibodies of Kv-SL and methods of diagnosing and treating diseases associated with expression of Kv-SL, and screening assays employing the protein, nucleotide, and antibody compositions.
    Type: Grant
    Filed: October 28, 1998
    Date of Patent: August 26, 2003
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John R. Forsayeth, Byron Zhao, Raymond A. Chavez